Buy & Sell Hologic, Inc. (HOLX) – Hologic, Inc. Price Today
Aura AI Summary
Key Stats
- $16.97BMarket Cap
- HealthSector
- -0.92%3M Drawdown
- $17.12BEnterprise Value
- -Dividend Yield
- 59 daysTypical Hold Time
Hologic, Inc. (HOLX) is currently valued at a market capitalization of $16.97B, with an enterprise value of $17.12B. Over the past 52 weeks, Hologic, Inc. has traded between a low of $54.28 and a high of $76.01, highlighting its annual price range. Over the past three months, Hologic, Inc. has recorded a drawdown of -0.92%, reflecting recent price volatility. On average, investors hold Hologic, Inc. for approximately 59 days, indicating typical investor behavior on the platform.
About Hologic, Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Most Recent News
Trump team ordered to discard all items from China on Air Force One amid spy fears
During President Trump's summit with Chinese President Xi Jinping, U.S. officials aboard Air Force One were instructed to discard all items received in China, including burner phones, badges, and lapel pins. This precaution addresses concerns over Ch...
US 30-year Treasury yields hit 5.12%, highest since 2007, amid global bond sell-off and UK debt concerns.
US 30-year Treasury bond yields surged 18 basis points to 5.12%, reaching levels not seen since July 2007, surpassing spikes from the 2023 gilt crisis. This rise reflects a global bond market sell-off and growing concerns over the UK's government deb...
Trip.com faces a major antitrust probe by SAMR, causing a 40% stock drop amid potential hefty fines.
Trip.com Group is under investigation by China's State Administration for Market Regulation (SAMR) for alleged monopolistic practices, triggered by complaints from small hotel operators. This probe has led to a sharp 40% decline in Trip.com's stock p...